1. In Vivo

Biotech Foundations: Networks And Lab Space Are As Crucial As Funding

 
• By William Masters

BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies. 

building blocks

The problem with Europe’s much discussed fragmented life sciences market, in contrast with US hubs like Boston, is perhaps most acute at the earliest stage. The continent’s abundance of scientists can struggle to find the resources to develop their hypotheses to the point where venture capital comes into play.

The Copenhagen, Denmark-based BioInnovation Institute (BII) aims to fill this crucial gap in the life sciences journey. This comes down...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.